Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Larazotide vs Vesugen
An educational, source-based comparison of Larazotide and Vesugen — how each peptide works, what it's researched for, and what to know before going deeper.
An octapeptide zonulin antagonist that helps maintain intestinal tight junction integrity, reducing paracellular permeability triggered by gluten in celiac disease.
- Celiac disease (Phase 3 completed)
- Intestinal barrier function ('leaky gut' research)
- Environmental enteropathy
- • Not yet FDA-approved.
- • Investigational; physician oversight required.
A synthetic tripeptide (Lys-Glu-Asp) in the Khavinson bioregulator family. Research indicates modulation of endothelial cell function and vascular wall gene expression, supporting vascular tone and microcirculation.
- Vascular endothelial function
- Microcirculation in aging
- Peripheral vascular disorders
- • Russian-origin research; independent replication limited.
- • Not FDA-approved.
Larazotide vs Vesugen — Key differences
- Class: Larazotide is classified as Gastrointestinal · Barrier, while Vesugen is Vascular · Bioregulator.
- Primary research focus: Larazotide — celiac disease (phase 3 completed); Vesugen — vascular endothelial function.
- Tag: Gut vs Vascular · Bioregulator.